Cofactor Genomics
Cofactor Genomics advances precision medicine with RNA-based diagnostics and predictive models.
Cofactor Genomics advances precision medicine with RNA-based diagnostics and predictive models.
Cofactor uses RNA and Predictive Immune Modeling to build better biomarkers and improve patient outcomes.rnrnLed by Jarret Glasscock and a group of expert human genome scientists,Cofactor has built a new category of diagnostic technology powered by unique and powerful RNA data models built on terabytes of data. rnrnThe team recently had their technology validation peer-reviewed by the organizations that set standards for diagnostic technology (CAP, AMP) and is publishing in the Journal of Molecular Diagnostics.
In addition, the team made news when Cancer Physicians who sit on the committee for patient treatment guidelines (NCCN) presented a clinical study using Cofactor’s technology showing superiority in predicting the patients who will respond to immunotherapy. This initial application is an acute problem recognized widely in the rapidly developing immunotherapy industry and represents north of a billion dollar TAM. rnrnAfter a number of recent key milestones, the team is taking the technology more broadly to 50% of cancers diagnosed in the US. rnrnCurrent investors include Menlo Ventures, DCVC, and Ascension Ventures (this last investor representing the funding arm for 13 National U.S. Healthcare Systems).
Companies similar to Cofactor Genomics include Circular Genomics, Immunai, Genomenon and Inform Genomics.
Cofactor Genomics was founded in 2015.
Cofactor Genomics' headquarters is located in St. Louis, MO, US.
Cofactor Genomics' most recent funding round was for $1.2M (USD) in August 2023.
As of Aug 2, 2023, Cofactor Genomics has raised a total of $28.9M (USD).
Cofactor Genomics has 14 employees as of Feb 5, 2024.
genomenon.com
